High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy [...]

Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and [...]

Stephanie C. Pero, Abhinav B. Nagulapally, Linda Mei, Fan Zhang,*, Giselle S. Sholler, David N. Krag, Girja S. Shukla, Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma, Annals of Clinical & Laboratory Science, vol. 52, no. 3, 2022

Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline M. Kraveka, William Ferguson, Peter Carmeliet, Andy De Deene, Lore Gijsen, Rakesh K. Jain, A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma Clin Cancer Research, [...]

Jacqueline M. Kraveka,  Elizabeth C. Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld, Elizabeth Kim, Abhinav B. Nagulapally, Karl J. Dykema, Valerie I. Brown, William D. Roberts, Deanna Mitchell,on E Dslin, Derek Hanson, Michael S. Isakoff, Randal K. Wada, Virginia L. Harrod, Jawhar Rawwas, Gina Hanna, William P. D. Hendricks, Sara A. Byron, Matija Snuderl, Jonathan [...]

Maximillian S Westphal 1, Eunjee Lee 1 2, Eric E Schadt 1 2, Giselle S Sholler 3 4, Jun Zhu, Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma,  Cancers (Basel). 2021 Dec 28;14(1):139.  doi: 10.3390/cancers14010139.

 Sara A. Byron*, William P. D. Hendricks*, Abhinav B. Nagulapally*,  Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E. Eslin, Deanna Mitchell, Albert Cornelius, William Roberts, Michael S. Isakoff, Javier E. Oesterheld, Randal K. Wada, Jawhar Rawwas, Kathleen Neville, Peter E. Zage.  Virginia L. Harrod, Genevieve Bergendahl, Elizabeth VanSickle, Karl Dykema, Jeffrey Bond, [...]

Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park, Giselle Saulnier Sholler, The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma, Cancer Medicine, July 2020, DOI: 10.1002/(ISSN)2045-7634

Shukla, G.S., S.C. Pero, Y. Sun, L. Mei, F. Zhang, G. Sholler, and D.N. Krag, Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models. Clin Transl Oncol, 2020 Jul;22(7):1094-1104

Izhar S. Batth, Long Dao, Arun Satelli, Abhisek Mitra, Sofia Yi, Hyangsoon Noh, Heming Li, Zachary, Brownlee, Shouhao Zhou, Jeffrey Bond,  Jing Wang,  Jonathan Gill, Giselle S. Sholler, Shulin Li, Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients, Int. J. Cancer., June 2020;1–10.